| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_644c03c3333a4447130f6dd66cfccfc4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f98e77d1aba3a9c2fb565cc42cc7c76f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2014-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcdfc8ff7dcd7c559a00224c97448140 |
| publicationDate |
2014-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2014209915-A |
| titleOfInvention |
RNA antagonist compounds for modulating β-catenin |
| abstract |
An oligomeric compound (oligomer) that targets β-catenin mRNA in cells and reduces β-catenin expression is provided. An oligomer of 10 to 50 nucleobases in length comprising a continuous nucleobase sequence of a total of 10 to 50 nucleobases, wherein the continuous nucleobase sequence is a mammalian β-catenin. An oligomer having at least 80% homology with the corresponding region of the nucleic acid encoding. Reduction of β-catenin expression is beneficial for various medical diseases such as hyperproliferative diseases including cancer. The present invention provides therapeutic compositions comprising oligomers and methods for modulating β-catenin expression using said oligomers, including therapeutic methods. [Selection figure] None |
| priorityDate |
2007-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |